Showing 611-620 of 7123 results for "".
Hoya ConBio - Tattoo Removal
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-tattoo-removal/19456/The Medlite is an optimal way to remove tattoos. Instructions accompanied by video demonstrations are shown.Hoya ConBio - Operation of the Medlite C6
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-operation-of-the-medlite-c6/19458/Operation of the Medlite C6 laser for skin renewal is demonstrated.Drug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Journal Club: AD's Impact on Mental Health
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-ads-impact-mental-health/28628/Practical Dermatology Editorial Board member Peter Lio, MD, chats with dermatologist Robert Sidbury, MD, MPH, about the Cureus article, "Investigation of the Impact of Atopic Dermatitis (AD) on Stress, Depression, Anxiety, and Suicidal Ideation: A Systematic Review and Meta-Analysis."How does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.Skin Cancer Prevention: Can Laser Therapy Help?
https://practicaldermatology.com/conferences/scale-2023/skin-cancer-prevention-can-laser-therapy-help/20205/Non-ablative fractional laser treatments may dramatically the reduce risk of skin cancer recurrence. Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss the science behind this intriguing finding.When Everyone Has “Skin in the Game”
https://practicaldermatology.com/issues/april-2025/when-everyone-has-skin-in-the-game/35622/In today’s dynamic medical and marketing world, partnerships with other practices, businesses, and organizations are ripe for the picking.Hair Restoration Redefined
https://practicaldermatology.com/topics/practice-management/hair-restoration-redefined/19254/See the ARTAS Robotic System in action.First, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.CSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.